Nucleotide sequence of theSaccharomyces cerevisiae CLN1andCLN2genes [PDF]
J. A. Hadwiger, S. I. Reed
openaire +3 more sources
Intrathecal enzyme replacement therapy for CLN2 disease [PDF]
openaire +1 more source
Conversion of a ventricular rickham reservoir to a subcutaneous chest port for repeated intraventricular enzyme replacement therapy: technical note and surgical considerations. [PDF]
Gopalka M +5 more
europepmc +1 more source
Evolution of Movement Disorders in Patients With CLN2-Batten Disease Treated With Enzyme Replacement Therapy [PDF]
OBJECTIVES: Neuronal ceroid lipofuscinosis type 2 (CLN2-disease) is an inherited childhood-onset neurodegenerative condition, with classical early features of speech delay, epilepsy, myoclonus, ataxia, and motor regression.
Soo, Audrey K +8 more
core
A cyclin-polarity feedback network ensures healthy cell proliferation. [PDF]
Peyran L +4 more
europepmc +1 more source
Difficulties in treating CLN2 through enzyme replacement therapy
Erlane Marques Ribeiro +8 more
openaire +1 more source
LC-HRMS-Based Metabolic Profiling of the REV-ERB Agonist SR9009 in Camel Liver Homogenate and Cunninghamella elegans for Anti-Doping Analysis. [PDF]
Palathinkal AB +6 more
europepmc +1 more source
Psychiatric manifestations in Neuronal ceroid lipofuscinoses. [PDF]
Della Vecchia S +5 more
europepmc +1 more source
Antibiotic treatment reveals the contributions of the gut microbiome to CLN2 disease in the central and enteric nervous system. [PDF]
Ziółkowska EA +9 more
europepmc +1 more source
PPARα and RXRα in the regulation of neuronal ceroid lipofuscinosis genes: implications for Batten disease therapy. [PDF]
Chandra S, Pahan K.
europepmc +1 more source

